来源：金融界 中银创新医疗混合A股票持仓前十占比合计70.60%，分别为：恒瑞医药（9.81%）、信达生物 （8.55%）、和黄医药（8.41%）、康方生物（8.35%）、康诺亚-B（8.32%）、科伦博泰生（7.87%）、 百济神州-U（6.24%）、荣昌生物（5.96%）、翰森制药（3.98%）、新诺威（3.11%）。 金融界2025年4月9日消息，中银创新医疗混合A(007718) 最新净值1.4557元，增长1.58%。该基金近1个 月收益率2.80%，同类排名22|3788；近3个月收益率27.12%，同类排名12|3756；今年来收益率20.98%， 同类排名24|3754。 简历显示：郑宁先生:中国,研究生、硕士。曾任泰康资产管理有限责任公司股票研究经理、高级股票研 究经理;中庚基金管理有限公司研究员、高级研究员(医药组组长)。2022年加入中银基金管理有限公司。 2022年7月1日担任中银创新医疗混合型证券投资基金基金经理。2022年10月13日担任中银医疗保健灵活 配置混合型证券投资基金基金经理。2023年2月28日任中银大健康股票型证券投资基金基金经理。 公开资料显示，中银创新医疗混合A基 ...

Investment Rating - The report suggests a positive outlook for the pharmaceutical industry, indicating a potential for outperformance compared to the overall market [27]. Core Insights - The report highlights the impact of the recent U.S. tariff measures, which include a 34% additional tariff on Chinese goods, and the subsequent Chinese countermeasures that may benefit domestic pharmaceutical companies [3][4][5]. - It emphasizes the growth in China's pharmaceutical exports, particularly to the U.S., which reached $19.05 billion in 2024, marking an 11.7% increase year-on-year [6][7]. - The report identifies specific sectors within the pharmaceutical industry that may benefit from the tariff situation, including blood products, high-end raw materials, medical devices, and innovative drugs [18][19]. Summary by Sections Tariff Impact - The U.S. has implemented a 34% tariff on Chinese goods, which affects a wide range of medical supplies and devices, while China has responded with similar tariffs on U.S. imports [4][5]. - The tariffs are expected to disrupt the supply of imported blood products, potentially increasing demand for domestic alternatives [18]. Trade Statistics - In 2024, China's total pharmaceutical trade amounted to $199.376 billion, with exports at $107.964 billion and imports at $91.412 billion, showing a slight decline in imports but a recovery in exports [6][11]. - The U.S. remains the largest market for Chinese pharmaceutical exports, accounting for 17.6% of total exports [7][11]. Sector Opportunities - Blood Products: The tariff on U.S. imports may lead to increased domestic production and sales of blood products, with companies like Tian Tan Biological, Hualan Biological, and others positioned to benefit [18]. - High-End Raw Materials: The report suggests that domestic manufacturers of critical raw materials and consumables may gain market share due to reduced competition from U.S. imports [18]. - Medical Devices: Companies focusing on high-value medical devices are recommended for their potential to capture market share from imported products [18]. - Innovative Drugs: The report encourages investment in companies involved in the development of innovative drugs, particularly those that can replace U.S. imports in oncology and vaccine sectors [19].

Market Performance - The Shanghai Composite Index rose by 0.15%, while the ChiNext Index increased by 0.24%. The STAR Market 50 Index and STAR Market 100 Index performed well, with increases of 1.12% and 1.14% respectively [4][5] - The healthcare, food and beverage, basic chemicals, banking, and electronics sectors showed positive performance, with returns of 1.88%, 0.84%, 0.72%, 0.46%, and 0.36% respectively. In contrast, the non-ferrous metals, comprehensive, steel, machinery, and construction sectors experienced declines [5][7] Market Sentiment - At the market close, there were 53 stocks hitting the upper limit and 30 stocks hitting the lower limit. Stocks that were limit-up yesterday showed weak performance today, with a closing return of -0.90%. Stocks that were limit-down yesterday had a closing return of -3.86% [9][12] - The sealing rate was 61%, down 15% from the previous day, and the consecutive sealing rate was 13%, down 11% from the previous day, marking a new low for the past month [14] Market Capital Flow - As of March 26, 2025, the margin trading balance was 1.9297 trillion yuan, with a financing balance of 1.9184 trillion yuan and a securities lending balance of 11 billion yuan. The margin trading balance accounted for 2.4% of the circulating market value [18][20] Premium and Discount - On March 26, 2025, the ETF with the highest premium was the Xinchang 50 ETF, with a premium of 0.77%. The ETF with the highest discount was the Penghua STAR Market Comprehensive Index ETF, with a discount of 0.39% [22][23] - The average discount rate for block trades over the past six months was 5.37%, with a discount rate of 10.33% on March 26, 2025, marking a new low for the past six months [26] Institutional Attention and Rankings - The stocks with the most institutional research in the past week included Huida Technology, Xindong Link, and Tangchen Beijian, with Huida Technology being researched by 126 institutions [32] - The stocks with the highest net inflow from institutional special seats on March 27, 2025, included C Huayuan, Hongbaoli, and Lixing Shares. Conversely, the stocks with the highest net outflow included Xinlai Yingcai and Sanwei Communication [35][38]

- The report does not contain any quantitative models or factors related to construction, testing, or evaluation

- The report does not contain any quantitative models or factors

Core Viewpoint - The recent decline in the ChiNext ETF (159964) presents a notable investment opportunity, as the valuation of the ChiNext index is considered attractive, especially with a significant increase of 40.10% over the past six months [1][3]. Group 1: Market Performance - As of March 24, 2025, the ChiNext index (399006) decreased by 1.22%, with mixed performance among constituent stocks [1]. - Notable gainers included Shenghong Technology (300476) up by 4.80%, and Anker Innovation (300866) up by 3.25%, while Triangular Defense (300775) led the declines with a drop of 7.31% [1]. - The ChiNext ETF (159964) fell by 1.16%, trading at 1.36 yuan, with a turnover of 2.71 million yuan and a turnover rate of 0.52% [1]. Group 2: Valuation Insights - The current price-to-earnings (P/E) ratio of the ChiNext has dropped below 30%, indicating a potential low-point for dollar-cost averaging investments [3]. - The top ten weighted stocks in the ChiNext index account for 50.5% of the index, with Ningde Times (300750) holding the largest weight at 20.39% [3][5]. Group 3: Sector Analysis - The market is experiencing a divergence in styles, with high turnover rates in popular sectors such as computing and machinery, suggesting a need for optimization in micro trading structures [3]. - There is an expectation for cyclical asset recovery driven by policy catalysts as market styles begin to balance [3].

Summary of the Conference Call for XinNuoWei Company Overview - **Company**: XinNuoWei - **Industry**: Biotechnology and Functional Foods Key Points and Arguments Financial Performance - In 2024, XinNuoWei's total revenue reached 1.98 billion yuan, with a net profit of approximately 53 million yuan, indicating a strategic shift towards biopharmaceuticals while maintaining its functional food business [4][5][6] - R&D expenses for 2024 amounted to 400 million yuan, reflecting a year-on-year increase of over 25% [2][4] Functional Foods and Raw Materials - The functional foods and raw materials segment maintained a leading position, achieving profits exceeding 425 million yuan despite price declines, with a gross margin of around 40% [2][5] - Production capacity exceeded 16,000 tons, capturing over 60% of the global market share [2][5] Biopharmaceuticals Development - Revenue from biopharmaceuticals reached 88 million yuan, primarily from two commercialized monoclonal antibody products [2][6] - Ten ADC (Antibody-Drug Conjugate) products are in clinical trials, with five expected to be submitted for approval in 2024 and three already approved [2][7] - Six products are advancing to Phase III trials, with plans to establish at least two overseas collaborations by 2025 [2][7] Clinical Trials and Research - Phase I clinical trials for ADC products have commenced, targeting second-line EGFR mutation lung cancer while exploring multiple indications [8] - The company is actively pursuing various indications in overseas clinical trials, including wild-type mutations and different lines of treatment [9] - The VDC project has enrolled 350 patients domestically, with a majority being mutation-type lung cancer cases [15] New Product Development - Two GLP-1 receptor agonists (FC fusion protein TD103 and a Semaglutide generic) are expected to submit for market approval in 2025, with potential approval between late 2026 and 2027 [3][18] - The J-One oral small molecule drug has received IDG and is preparing for Phase I trials [16] Market and Regulatory Environment - The company is in communication with regulatory bodies like the FDA and CDE regarding the EGFR-TKI project, with plans for further discussions in April and May 2025 [17] - The company is awaiting updates on the Anhui procurement process, with no clear information available yet [14] Strategic Focus and Future Outlook - XinNuoWei is focusing on expanding its ADC and GLP-1 product lines while exploring new targets in gastrointestinal tumors and dual-target long-acting formulations [12][18] - The company aims to complete two business development transactions in 2025, having already finalized one [18][25] Challenges and Considerations - The company faces challenges in expanding wild-type sample proportions in clinical trials and navigating regulatory requirements for breakthrough therapy designations [12][17] - There is uncertainty regarding the potential rebound of caffeine prices in the market, with current stability observed [19] Conclusion - XinNuoWei is strategically positioned to enhance its biopharmaceutical portfolio while maintaining its leadership in functional foods, with significant investments in R&D and clinical trials aimed at future growth and market expansion [2][4][6][18]

Financial Performance - The net profit attributable to shareholders for 2024 was CNY 53.73 million, a decrease of 87.63% compared to the previous year[3]. - The company's operating revenue for 2024 was CNY 1,980,753,000, a decrease of 21.98% compared to CNY 2,538,713,470 in 2023[19]. - The net profit attributable to shareholders for 2024 was CNY 53,726,319, representing an 87.63% decline from CNY 434,435,597 in 2023[19]. - The net cash flow from operating activities for 2024 was negative CNY 1,235,054,400, a decrease of 271.26% compared to CNY 721,139,552 in 2023[19]. - The total assets at the end of 2024 were CNY 6,022,115,000, a decrease of 19.41% from CNY 7,472,208,450 at the end of 2023[19]. - The basic earnings per share for 2024 was CNY 0.0384, down 87.65% from CNY 0.3110 in 2023[19]. - The company reported a significant drop in net profit excluding non-recurring items, which was CNY 42,341,883, down 94.31% from CNY 743,672,985 in 2023[19]. - The total revenue for 2024 was approximately ¥1,980,753,001.9, representing a decrease of 21.98% compared to ¥2,538,713,472.3 in 2023[72]. - The revenue from functional foods and raw materials accounted for ¥1,840,312,457.8, which is 92.91% of total revenue, down 24.90% from ¥2,450,349,584.8 in the previous year[72]. Research and Development - Research and development expenses for the year totaled CNY 842.20 million, an increase of CNY 170.80 million, representing a year-on-year growth of 25.44%[3]. - The company is focusing on the development of biopharmaceuticals, including ADCs and mRNA vaccines, as part of its innovation strategy[30]. - The company aims to strengthen its research and development capabilities, with a commitment to meeting clinical needs and advancing antibody therapies[32]. - The number of R&D personnel increased to 415 in 2024, representing an 8.36% growth from 383 in 2023[88]. - R&D investment accounted for 42.52% of total revenue in 2024, up from 26.45% in 2023[88]. - The company has over 20 products in the research pipeline, with several achieving important progress during the reporting period[81]. - The company invested 842.2 million yuan in R&D in 2024, an increase of 25.44% compared to the previous year[53]. Biopharmaceutical Development - The pipeline for biopharmaceutical innovation now exceeds 20 projects, with several products making significant progress during the reporting period[4]. - The company received approval for the launch of Enlansumab injection and Omalizumab injection in 2024, with additional projects entering critical clinical trial phases[4]. - The company has established a biopharmaceutical innovation platform, extending its business chain into the field of innovative biopharmaceuticals[38]. - The company is developing a biosimilar to Omalizumab (Zhiluo®), which has shown high similarity in quality, safety, and efficacy compared to the original drug in clinical studies[41]. - SYS6010, a breakthrough therapy for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC), is under development and has shown significant efficacy compared to standard treatments[42]. - The company has multiple ongoing clinical trials for various drugs, including SYS6023 (ADC) for advanced solid tumors and SYS6016 (mRNA vaccine) for RSV-related lower respiratory diseases[42]. - The company has received approval for two mRNA vaccine products for emergency use in China, enhancing its product portfolio[47]. Market and Competitive Landscape - The biopharmaceutical industry in China is experiencing strong growth driven by policy support, increasing market demand, and technological advancements, with the market expected to outpace global growth rates[32]. - The company is the largest producer of synthetic caffeine globally and serves major international beverage companies such as PepsiCo, Coca-Cola, and Red Bull[40]. - The company is focusing on developing new products such as uracil and theobromine to create differentiated advantages in the market[56]. - The company has established stable partnerships with over 200 chain pharmacy enterprises across nearly 30 provincial administrative regions, forming a nationwide sales network[68]. - The company has a strong market influence and brand recognition in the functional food and raw materials sector, supported by its extensive R&D experience[47]. Governance and Management - The company emphasizes information disclosure, adhering to regulations to provide accurate and timely information to investors[139]. - The governance structure of the company aligns with regulatory requirements, with no significant discrepancies identified[143]. - The company operates independently from its controlling shareholders in terms of business, assets, personnel, and finance, ensuring a complete separation in operations[144]. - The company has established a strategic focus on building a comprehensive biopharmaceutical innovation platform through its investment in Giant Stone Bio[119]. - The company has a clear governance structure with separate decision-making and supervisory bodies, ensuring independent operations[145]. Environmental and Social Responsibility - The company strictly adheres to environmental protection laws and regulations, including the Environmental Protection Law and various pollution prevention standards[188]. - The company has completed the integration of its subsidiary, Giant Stone Biological Pharmaceutical Co., Ltd., into unified management[183]. - The company has made continuous investments in environmental protection to ensure compliance with pollution discharge standards[196]. - The company has engaged qualified third-party monitoring agencies to ensure compliance with environmental standards[195]. - The company is committed to sustainable development, increasing investments in environmental protection and clean production technologies[123]. Shareholder Engagement and Dividends - The profit distribution plan approved by the board includes a cash dividend of CNY 0.20 per 10 shares, with no bonus shares issued[5]. - The company approved a cash dividend of RMB 3.2 per 10 shares, totaling RMB 374,161,265.28, based on a share capital of 1,169,253,954 shares[177]. - The cash dividend distribution accounted for 100% of the total distributable profit of RMB 1,334,850,119.75[178]. - The annual shareholders' meeting had a participation rate of 75.44% on April 9, 2024, indicating strong investor engagement[148]. Challenges and Risks - The company faces market competition risks, particularly in the innovative drug sector, where rapid product updates may threaten existing advantages[124]. - Raw materials constitute a significant portion of operating costs, and any price increases could adversely affect profitability if not managed effectively[127]. - Exchange rate fluctuations pose a risk to the company's operations, particularly in its export business, which is a key source of revenue and profit[128]. - The pharmaceutical industry faces increasing regulatory scrutiny, which may raise operational costs and impact future profitability if quality standards are further tightened[125].

| | 国泰君安证券 | | --- | --- | | | GUOTAI JUNAN SECURITIES | 目 录 | | 每日报告回放（2025-03-13 09:00——2025-03-14 15:00） 2 | | | --- | --- | --- | |  | 事件点评：《通胀降温或为暂时，仍需警惕"滞胀交易"》2025-03-13 | 2 | |  | A 股策略观察：《外资交易热度抬升，杠杆资金延续流入》2025-03-14 | 3 | |  | 行业更新：煤炭《下行风险释放，4 月有望进入上升通道》2025-03-14 | 3 | |  | 行业专题研究：计算机《DeepSeek 重构算力基建长期价值的认知》2025-03-14 | 4 | |  | 行业首次覆盖：化学制剂《抗肿瘤疗法持续迭代，国产新药迎来突破》2025-03-13 | 5 | |  | 行业日报/周报/双周报/月报：环保《首批 CCER 登记，全国碳市场加速完善》2025-03-13 | 6 | |  | 行业深度研究：公用事业《从成长到红利，城燃行业价值重构》2025-03-13 | 7 | |  | ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [5] Core Viewpoints - The AI concept has experienced a pullback, but the upward momentum for innovative drugs is expected to continue [1][2] - The pharmaceutical index fell by 2.15% last week, outperforming the CSI 300 index by 0.07 percentage points, ranking 25th in industry performance [10] - The healthcare services sub-sector has shown the highest growth since the beginning of 2025, with a rise of 12.31% [16] - The report highlights the strong performance of innovative drugs and companies with positive earnings forecasts, such as Nocera Health and Newnovel [19][31] Market Performance Summary - The pharmaceutical index has increased by 4.17% year-to-date, outperforming the CSI 300 index by 5.31 percentage points, ranking 12th in industry performance [10] - The best-performing stocks in the A-share market last week included Nocera Health (+20.98%), Changyao Holdings (+20.96%), and Shanghai Yizhong (+18.78%) [19] - In the Hong Kong stock market, 30 out of 106 pharmaceutical stocks rose, accounting for 28.3% [23] Sub-industry Performance - The sub-industry with the smallest decline last week was Traditional Chinese Medicine, down 0.35%, while the largest decline was in pharmaceutical commerce, down 3.44% [14] - Year-to-date, the Traditional Chinese Medicine sub-sector has decreased by 5.29%, while healthcare services have increased by 12.31% [16] Industry News and Policies - Starting March 1, Guangxi will implement centralized procurement for large medical equipment, aiming to reduce costs through bulk purchasing [27][28] - Huadong Medicine's ADC innovative drug has received orphan drug designation from the FDA, which provides various incentives for the company [29] Company Announcements - Notable company announcements include Nocera Health's significant R&D progress and Newnovel's exclusive cooperation agreement with RadianceBiopharma, potentially worth $1.23 billion [19][31]